Allergen-Induced Bronchoconstriction in Asthmatic Children (5)
BN52021 remained soluble in HBSS when cooled to room temperature before use. HBSS containing DM SO of lOMold dilution (weight/volume) was used as placebo. As both BN52021 and DMSO were highly diluted, no evident bitter taste or odor could be detected. Moreover, only those who showed less than 10 percent decrease in FEV, after inhaling placebo or drug would participate in the study. antibiotic levaquin
Pulmonary function was measured (using Microspiro Hi-298, Chest Corporation, Tokyo, Japan). Bronchial provocations were performed according to the standard method of Chai et alw and Rosenthal. A nebulizer (DeVilbiss model 646) was connected to a dosimeter consisting of an input solenoid valve delivering 20 psi of compressed air that generated aerosols of particle size of 2 to 5 |i.m, and a timer was set at 0.5 s for each inspiratory breath. The timing of the opening of the valve was manually triggered by the patient through the hand-held reset switch and the thermistor breath sensing unit. Each breath of testing agent was delivered from functional residual capacity to inspiratory capacity. The bronchial provocation tests were stopped if a greater than 20 percent decrease of FEV, of baseline was reached, or frank asthmatic attack occurred or no significant drop in FEV, was observed even after inhaling the highest dose of stimulants.